NSRXNasus Pharma Ltdvs its industry peers
A metric-by-metric comparison of Nasus Pharma Ltd against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NSRXEsta | $31M#3 | — | 11.3x#1 | 0.0x#1 | — | -282.2%#3 | -0.4%#1 | -211.6%#1 | — | — | — | — |
| NGEN | $182M#2 | — | — | — | — | — | — | — | — | — | — | — |
| NIKA | — | — | — | — | — | 20.2%#1 | — | — | — | — | — | — |
| NRSN | $224M#1 | — | — | — | — | -9.0%#2 | — | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice